Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
INVION COMPLETES DOSING OF FIRST SIX PATIENTS IN PHASE I/II NON-MELANOMA SKIN
CANCER TRIAL
Highlights:
First six patients have been successfully dosed in Invion’s open label Phase I/II nonmelanoma skin cancer (NMSC) trial using topical INV043.
This is an important milestone as it triggers a review by the Safety Review Committee
(SRC) of the first part of the trial, which focuses on patient safety.
The SRC will meet in the coming weeks to evaluate the safety data and decide if there
is a need to adjust the next stage of the trial to optimise outcomes.
Invion recently appointed a second clinical site in Queensland, Cornerstone
Dermatology, to complement the existing site at Veracity Clinical Research.
Skin cancer is one of the world’s most common cancers and NMSC constitutes >98% of
all skin cancers1 with the global treatment market to hit US$21.1 billion by 20322.
MELBOURNE (AUSTRALIA) 02 May 2025: Invion Limited (ASX: IVX) (“Invion” or the “Company”)
is pleased to announce the completion of dosing of the first six patients in its Phase I/II nonmelanoma skin cancer (NMSC) trial in Queensland.
This is an important milestone as it triggers a review by the Safety Review Committee (SRC) of
the first part of the trial, which focuses on patient safety using Invion’s treatment, and clears
the way for the next stage, following appraisal of the results of the six patients in the coming
weeks.
The SRC will determine if there is a need to adjust the dose-light interval (time between
applying INV043 and the light treatment) and/or to expand the trial to also include superficial
basal cell carcinoma (sBCC), instead of only cutaneous squamous cell carcinoma (cSCC).
Invion will provide a further update after it receives the SRC’s report.
The six patients came from two three-patient cohorts and were part of a light dose escalation
study (the dose of INV043 remained constant), where two different light intensity doses were
evaluated.
Invion recently appointed a second clinical site, Cornerstone Dermatology. The first six patients
were treated at either Veracity Clinical Research or Cornerstone Dermatology.
The trial is designed to evaluate the safety and efficacy of its lead drug candidate INV043, a
novel photosensitiser developed in Australia for use in Photodynamic Therapy (PDT) for the
treatment of cancer, in a topical ointment formulation.
Skin cancer is one of the world’s most common cancers and NMSC makes up over 98% of all
skin cancers1 with the global treatment market to hit US$21.1 billion by 20322. The prevalence
of the disease highlights the urgent need for effective and affordable treatments with minimal
side effects.
1
2
https://www.cancercouncil.com.au/skin-cancer/about-skin-cancer/
https://www.fortunebusinessinsights.com/skin-cancer-treatment-market-102806
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.com
ASX ANNOUNCEMENT
Currently, the mainstream treatment for SCC and BCC is surgery, which can lead to permanent
scarring. Preclinical studies undertaken at the Hudson Institute of Medical Research showed
the potential for INV043 to regress cancers without scarring and with minimal pain.
More details on the Phase I/II NMSC trial design can be found at:
https://investors.inviongroup.com/announcements/6690510.
This announcement was approved for release by the Board of Directors.
____________________________________________
Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate
in discussions: https://investors.inviongroup.com/
Investor and Media enquiries:
Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com
Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com
About Invion
Invion is a life-science company that is leading the global research and development of the
Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious
diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive
distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan
and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive
rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau,
the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently
acquired the rights to the United States, Canada and Hong Kong for infectious diseases.
Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group
Limited. Invion is listed on the ASX (ASX: IVX).
About Photodynamic Therapy (PDT)
Invion is developing PhotosoftTM technology as a novel next generation Photodynamic
Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and
promote an anti-cancer immune response. Less invasive than surgery and with minimal side
effects, PDT offers an alternative treatment option aimed at achieving complete tumour
regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity
across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the
potential to address the global challenge of antibiotic-resistant “superbugs”.
Invion Limited ABN 76 094 730 417
100 Albert Road, South Melbourne, VIC 3205
P: +61 3 9692 7222 W: www.inviongroup.com
Share your feedback
Discover